Clinuvel Pharmaceuticals Ltd (ASX: CUV) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Clinuvel Pharmaceuticals Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Clinuvel Pharmaceuticals Ltd (ASX: CUV)
Latest News
Share Fallers
Why Afterpay, Clinuvel, OceanaGold, & Zip Co shares sank lower today
Share Market News
4 of the biggest news pieces from the ASX200 this week
Share Gainers
These were the best-performing shares on the ASX 200 last week
Share Market News
The latest Aussie ETF FUM flow data might shock "Big Short" Michael Burry
Share Gainers
ALL ORDINARIES finishes lower Thursday: 8 ASX shares you missed
Share Market News
ASX 200 lunch time report: CBA & Clinuvel lower, Brambles higher
Share Fallers
Why the Clinuvel share price dropped 21% today
Share Gainers
3 things you missed on the ASX on Wednesday
52-Week Highs
Why these All Ords shares just rocketed to 52-week highs
Share Fallers
ALL ORDINARIES finishes lower Wednesday: 8 ASX shares you missed
Share Gainers
Why Cleanaway, Clinuvel, Saracen, & SeaLink shares raced higher today
Share Market News
Why the Clinuvel share price is up 38% today
Frequently Asked Questions
-
Yes, Clinuvel Pharmaceuticals has historically paid one unfranked shareholder dividend a year.
-
Clinuvel Pharmaceuticals generally pays its shareholder dividend in September.
-
Clinuvel Pharmaceuticals does not have a dividend reinvestment plan.
-
Clinuvel Pharmaceuticals Limited listed on the ASX on 13 February 2001.
Dividend Payment History Data provided by Morningstar.
Ex-Date | Amount | Franking | Type | Payable |
---|---|---|---|---|
05 Sep 2023 | $0.0500 | 100.00% | Final | 20 Sep 2023 |
06 Sep 2022 | $0.0400 | 100.00% | Final | 21 Sep 2022 |
02 Sep 2021 | $0.0250 | 0.00% | Final | 17 Sep 2021 |
03 Sep 2020 | $0.0250 | 0.00% | Final | 18 Sep 2020 |
04 Sep 2019 | $0.0250 | 0.00% | Final | 19 Sep 2019 |
21 Sep 2018 | $0.0200 | 0.00% | Final | 08 Oct 2018 |
CUV ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
---|---|---|---|---|---|
YesNo |
About Clinuvel Pharmaceuticals Ltd
Clinuvel Pharmaceuticals Ltd (ASX: CUV) is an Australian-based global biopharmaceutical company developing drugs for the treatment of genetic and vascular disorders. Its principal product SCENESSE is a drug for an inherited disorder, erythropoietic protoporphyria, that causes an intolerance to light.
Its pioneering work aims at preventing the symptoms of skin diseases related to exposure to UV radiation and at repigmentation of the skin due to depigmentation disorders. Geographically, the company derives the majority of its revenue from its US and European markets.
CUV Share Price History Data provided by Morningstar.
Date | Close | Change | % Change | Volume | Open | High | Low |
---|---|---|---|---|---|---|---|
29 May 2024 | $15.31 | $-0.38 | -2.42% | 110,077 | $15.49 | $15.58 | $15.19 |
28 May 2024 | $15.69 | $0.07 | 0.45% | 98,041 | $15.68 | $15.98 | $15.58 |
27 May 2024 | $15.62 | $0.05 | 0.32% | 25,281 | $15.60 | $15.67 | $15.49 |
24 May 2024 | $15.57 | $0.17 | 1.10% | 48,359 | $15.38 | $15.63 | $15.25 |
23 May 2024 | $15.40 | $0.38 | 2.53% | 51,563 | $15.00 | $15.52 | $15.00 |
22 May 2024 | $15.02 | $-0.43 | -2.78% | 61,584 | $15.40 | $15.60 | $15.00 |
21 May 2024 | $15.45 | $0.06 | 0.39% | 48,398 | $15.34 | $15.51 | $15.18 |
20 May 2024 | $15.39 | $-0.06 | -0.39% | 34,804 | $15.46 | $15.49 | $15.12 |
17 May 2024 | $15.45 | $0.19 | 1.25% | 109,537 | $15.26 | $15.59 | $15.20 |
16 May 2024 | $15.26 | $0.18 | 1.19% | 74,738 | $15.14 | $15.31 | $15.01 |
15 May 2024 | $15.08 | $-0.54 | -3.46% | 76,813 | $15.40 | $15.56 | $15.03 |
14 May 2024 | $15.62 | $0.46 | 3.03% | 97,417 | $15.08 | $15.67 | $15.08 |
13 May 2024 | $15.16 | $-0.05 | -0.33% | 40,131 | $15.20 | $15.21 | $14.90 |
10 May 2024 | $15.21 | $0.30 | 2.01% | 60,345 | $14.92 | $15.28 | $14.92 |
09 May 2024 | $14.91 | $-0.56 | -3.62% | 61,862 | $15.49 | $15.50 | $14.90 |
08 May 2024 | $15.47 | $0.08 | 0.52% | 54,127 | $15.34 | $15.59 | $15.27 |
07 May 2024 | $15.39 | $0.39 | 2.60% | 66,623 | $15.00 | $15.60 | $15.00 |
06 May 2024 | $15.00 | $0.14 | 0.94% | 41,423 | $14.85 | $15.08 | $14.85 |
03 May 2024 | $14.86 | $0.00 | 0.00% | 45,805 | $14.93 | $15.07 | $14.76 |
02 May 2024 | $14.86 | $-0.20 | -1.33% | 76,148 | $15.07 | $15.10 | $14.83 |
01 May 2024 | $15.06 | $0.01 | 0.07% | 70,978 | $15.10 | $15.29 | $15.00 |
30 Apr 2024 | $15.05 | $-0.27 | -1.76% | 33,809 | $15.29 | $15.35 | $15.01 |
Director Transactions Data provided by Morningstar.
Date | Director | Type | Amount | Value | Notes |
---|---|---|---|---|---|
24 Nov 2023 | Philippe Wolgen | Buy | 301,125 | $5,119,125 |
Conversion of securities.
|
24 Nov 2023 | Philippe Wolgen | Transfer | 3,124,097 | $53,109,649 |
Off-market transfer. Assuming off market transfer of shares
|
24 Nov 2023 | Philippe Wolgen | Expiry | 1,212,625 | $20,614,625 |
As advised by the company. Lapsed, 3,01,125 Rights
|
24 Nov 2023 | Philippe Wolgen | Transfer | 3,124,097 | $53,109,649 |
Off-market transfer. Assuming off market transfer of shares
|
24 Nov 2023 | Philippe Wolgen | Exercise | 301,125 | $5,119,125 |
Conversion of securities.
|
19 Sep 2023 | Philippe Wolgen | Buy | 1,850 | $29,813 |
On-market trade.
|
26 Jun 2023 | Philippe Wolgen | Transfer | 3,120,715 | $53,894,748 |
Off-market transfer. Assuming off-market transfer of shares
|
26 Jun 2023 | Philippe Wolgen | Transfer | 3,120,715 | $53,894,748 |
Off-market transfer. Assuming off-market transfer of shares
|
26 Jun 2023 | Philippe Wolgen | Buy | 1,532 | $27,147 |
On-market trade.
|
Directors & Management Data provided by Morningstar.
Name | Title | Start Date | Profile |
---|---|---|---|
Ms Brenda Mary Shanahan | Non-Executive Director | Dec 2007 |
Mrs Shanahan has more tha 20 year's of experience in medical R&D and commercialisation. She is currently a non executive director of Phoslock Water Solutions Ltd
|
Mrs Susan (Sue) Smith | Non-Executive Director | Sep 2019 |
Mrs Smith is the Chief Executive Officer of the Independent Doctors Federation, a membership organisation representing practicing physicians within the UK independent healthcare sector. Mrs Smith also manages a consultancy business, providing advisory services to a range of healthcare organisations, investors and boards of directors. Prior to her current roles Mrs Smith has a career, serving for 14 years as Chief Executive Officer of The Princess Grace Hospital, London, and 11 years as the Chief Executive Officer of The Portland Hospital for Women and Children, London. Based in London, Mrs Smith is also Non-Executive Board Chair of Women's Health (London West One) Ltd, a specialist medical practice, Non-Executive Director of Elite Medicine Ltd, a precision medicine company, and a Trustee of the HCA International Foundation.
|
Dr Philippe J Wolgen | Chief Executive OfficerManaging Director | Dec 2005 |
Dr Wolgen is currently leading the Group's expansion, with an immediate focus on the US and the further development of the product pipeline for various market segments. His focus has been to establish a professional management team to execute the corporate objectives set and prepare next generation of managers.
|
Dr Karen Agersborg | Non-Executive Director | Jan 2018 |
Dr Agersborg had previously worked at Reading Hospital, West Reading and at Suburban Hospital, Norristown as Clinical Endocrinologist and served as Chief, Endocrinology, Diabetes, Metabolism at Chestnut Hill Hospital. Dr Agersborg had a career in managing commercial sales & distribution at Wyeth Pharmaceuticals (formerly Ayerst Laboratories). Dr Agersborg is also integral to setting US commercial strategy, pending US approval of SCENESSE, a decision on an approval expected later in 2019.
|
Dr Jeffrey Rosenfeld | Non-Executive ChairmanNon-Executive Director | Nov 2019 |
Dr Rosenfeld has experience in senior healthcare and research executive roles and career in the Australian Army Reserve. He was the Founding Director of Monash University Institute of Medical Engineering (MIME-Melbourne) and acted as Board Chair for the Security and Health Executive Leadership Institute at The University of Melbourne. For 15 years Dr Rosenfeld was Director of Neurosurgery at the Alfred Hospital, concurrently holding for nine years the position of Professor and Head of the Department of Surgery at Monash University. Dr Rosenfeld is an active member of the Melbourne community and is involved in various charitable causes. He has devoted much of his time to the Australian-Aid funded Pacific Islands Project for transfer of clinical skills and knowhow to healthcare professionals in Papua New Guinea, Fiji and the Solomon Islands. One of Australia's senior and experienced military surgeons, Dr Rosenfeld served on eight deployments to Rwanda, Bougainville, East Timor, the Solomon Islands and Iraq. Having attained the rank of Major General, Dr Rosenfeld is also a former Surgeon General of the Australian Defence Force and remains active in defence and veterans' affairs organisations.In 2018, he received the International Lifetime Recognition Award of the American Association of Neurological Surgeons.
|
Dr Emilie Rodenburger | Non-Executive Director | Apr 2024 |
Dr Rodenburger previously worked with the CLINUVEL Group for over a decade in clinical development roles in Australia, the USA and Europe. Dr Rodenburger spent four years with Roche in senior clinical roles. Based in the UK, Dr Rodenburger will oversee CLINUVEL global clinical program.
|
Mr Darren Keamy | Chief Finance OfficerCompany Secretary | Dec 2005 |
-
|
Darren Keamy | Chief Finance OfficerCompany Secretary |
-
|
Top Shareholders Data provided by Morningstar.
Name | Shares | Capital |
---|---|---|
HSBC Custody Nominees (Australia) Ltd | 11,280,990 | 22.83% |
BNP Paribas Nominees Pty Ltd Acf Clearstream | 5,679,762 | 11.50% |
BNP Paribas Nominees Pty Ltd | 5,312,764 | 10.75% |
J P Morgan Nominees Australia Pty Ltd | 4,390,776 | 8.89% |
Dr Philippe Jacques Wolgen | 3,122,247 | 6.32% |
Citicorp Nominees Pty Ltd | 3,014,759 | 6.10% |
Ender 1 LLC | 2,590,824 | 5.24% |
BNP Paribas Nominees Pty Ltd (ii) | 1,482,356 | 3.00% |
Emilino Group Pty Ltd | 603,447 | 1.22% |
National Nominees Ltd | 548,371 | 1.11% |
Dr Mark Edwin Badcock | 440,085 | 0.89% |
Mr David William Trevorrow | 229,600 | 0.46% |
Mr David John Lewis | 187,000 | 0.38% |
HSBC Custody Nominees (Australia) Ltd a/c 2 | 180,199 | 0.36% |
Mr Trent Sheldon Redding | 179,480 | 0.36% |
Mr Darren Michael Keamy | 178,588 | 0.36% |
Rusty Hammer Pty Ltd | 156,892 | 0.32% |
Dr Dennis Wright | 156,874 | 0.32% |
Mr Simon John Bown | 146,000 | 0.30% |
BNP Paribas Noms (NZ) Ltd | 130,710 | 0.26% |